OncoMatch/Clinical Trials/NCT06333262
Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia
Is NCT06333262 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Pirtobrutinib and Obinutuzumab for chronic lymphocytic leukemia.
Treatment: Pirtobrutinib · Obinutuzumab — This study will evaluate fixed-duration therapy with pirtobrutinib and obinutuzumab given over 12 cycles (approximately 1 year) as first-line treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL or SLL).
Check if I qualifyExtracted eligibility criteria
Cancer type
Chronic Lymphocytic Leukemia
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Lab requirements
Blood counts
Adequate organ and bone marrow function as defined by the study protocol
Kidney function
Adequate organ and bone marrow function as defined by the study protocol
Liver function
Adequate organ and bone marrow function as defined by the study protocol
Adequate organ and bone marrow function as defined by the study protocol
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- New England Cancer Specialists · Scarborough, Maine
- Beth Israel Deaconess Medical Center · Boston, Massachusetts
- Brigham & Women's Hospital · Boston, Massachusetts
- Dana-Farber Cancer Institute · Boston, Massachusetts
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify